Christopher Gibson, Ph.D., is our co-founder, Chief Executive Officer since the company’s founding in November 2013. Dr. Gibson was also Chairman of our Board from the company’s founding until he asked, with the support of the rest of the Board, for Dr. R. Martin Chavez to accept a position of Chairman in January 2021.
Previously, Dr. Gibson was an M.D./Ph.D. student at the University of Utah. After obtaining his Ph.D., he withdrew from medical school to found Recursion. He has undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) Rice University. He has served as a Founding Chairman of the Board of BioHive (the Utah life science collective and branding effort, composed of therapeutics, diagnostics, medical device and health IT companies, along with the companies that support them and the public sector) since November 2020. He also serves as a Board member of BioUtah (the Utah life science industry association) since January 2019, Board member of the Recursion Foundation (our not-for-profit entity seeking to promote corporate social responsibility) since November 2019, through which he is on the Board of Altitude Lab (an incubator/accelerator focused on creating the next generation of diverse biotech founder in Utah) since July 2020.
Dr. Gibson has also served on the Cures Acceleration Network Review Board since September 2020. Dr. Gibson is co-author of more than a dozen peer-reviewed studies in a variety of journals including Nature, Nature Protocols, Circulation, the Journal of Clinical Investigation, Molecular Pharmaceutics, PloS One, and Diabetes. Our Board believes Dr. Gibson is qualified to serve on our Board because of his scientific and technical background and his knowledge and perspective of the Company.
What is Christopher Gibson's net worth?
The estimated net worth of Christopher Gibson is at least $7.17 million as of April 3rd, 2024. Dr. Gibson owns 978,524 shares of Recursion Pharmaceuticals stock worth more than $7,172,581 as of April 19th. This net worth estimate does not reflect any other investments that Dr. Gibson may own. Additionally, Dr. Gibson receives an annual salary of $695,180.00 as CEO at Recursion Pharmaceuticals. Learn More about Christopher Gibson's net worth.
How old is Christopher Gibson?
What is Christopher Gibson's salary?
How do I contact Christopher Gibson?
Has Christopher Gibson been buying or selling shares of Recursion Pharmaceuticals?
In the last ninety days, Christopher Gibson has sold $353,600.00 of Recursion Pharmaceuticals stock. Most recently, Christopher Gibson sold 40,000 shares of the business's stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $8.84, for a transaction totalling $353,600.00. Following the completion of the sale, the chief executive officer now directly owns 978,524 shares of the company's stock, valued at $8,650,152.16. Learn More on Christopher Gibson's trading history.
Who are Recursion Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Recursion Pharmaceuticals?
In the last year, insiders at the sold shares 70 times. They sold a total of 1,443,105 shares worth more than $13,646,266.83. The most recent insider tranaction occured on April, 17th when CFO Michael Secora sold 23,124 shares worth more than $175,279.92. Insiders at Recursion Pharmaceuticals own 20.0% of the company.
Learn More about insider trades at Recursion Pharmaceuticals. Information on this page was last updated on 4/17/2024.
